Andrew Aijian

Senior Project Leader

DeciBio Consulting

×

Andrew Aijian

Senior Project Leader

Dr. Andrew Aijian is a Sr. Project Leader at DeciBio Consulting, where he leads market landscape, product development, and strategy engagements for clinical diagnostic, pharmaceutical, and research tools companies, with an emphasis on oncology biomarkers and diagnostics. Prior to DeciBio, Andrew obtained his Ph.D. in Biomedical Engineering from UCLA, focusing on the development of microfluidic research tools for biomedical applications. He obtained his B.S. in Chemical and Biomolecular Engineering from the University of Notre Dame.

Jeff Allard

President

Lakeside Life Science

×

Jeff Allard

President

Dr. Allard is a biochemist and as President of Lakeside Life Science provides consulting services and biospecimens to the biotechnology industry. He served most recently as Director of Development for Caris Life Sciences where he designed and implemented a Product Development System, designed multiple clinical and regulatory strategies for novel multiplex oncology tests, wrote clinical protocols for prospective research and PMA-submission trials, and designed a Patient Registry. As Vice President and Chief Scientific Officer of Fujirebio Diagnostics, Inc. (FDI), Dr. Allard directed the Applied Research, Product Development, Clinical Affairs, Regulatory Affairs and Process Engineering Departments. He directed the US introduction of the Mesomark Assay as a Humanitarian Use Device for monitoring patients with mesothelioma. He also managed clinical trials leading to FDA clearance of HE4 for monitoring and for CA 125/HE4 and the ROMA algorithm for differential diagnosis in women with pelvic mass. In addition, he managed FDI’s expanding global network of in-licensing institutions, and administered an international program in Clinical Research. He also managed all intellectual property for FDI. Prior to joining FDI in 2004, Dr. Allard previously held positions as Vice President of Clinical Research and Development for Immunicon Corporation (Currently Veridex, LLC, a division of Johnson & Johnson) where he designed and managed clinical trials that led to worldwide introduction of the CellSearch Assay for measurement of circulating tumor cells (CTC). Dr. Allard designed three clinical trials that led to FDA clearance of CTC for prediction of overall survival and progression free survival in patients with breast, colorectal and prostate cancers. He was also Research Fellow and headed the effort in Clinical and Regulatory Oncology for Bayer Corporation (currently Siemens Healthcare Diagnostics) where he introduced novel immunoassays for complexed PSA and serum HER-2/neu along with a number of known cancer biomarkers. Prior to joining Bayer, Dr. Allard was a Diagnostics Researcher for E.I. du Pont de Nemours (also currently a division of Siemens Medical Solutions Diagnostics).

Dr. Allard is an inventor on 12 patents for novel technologies including new tests for gynecologic cancers, circulating tumor cells, complexed PSA for early detection of prostate cancer, and other diagnostic technologies. He is an author of over 50 manuscripts, and has received numerous awards including the Professional Achievement Award from Idaho State University.

Flora Berisha

Director of Companion Diagnostics

Daiichi Sankyo Pharma

×

Flora Berisha

Director of Companion Diagnostics

Flora Berisha is a Director of Companion Diagnostics, at Daiichi Sankyo Pharma. Flora received her BS in Biochemistry and Master Degree in Biology from City University of New York. She currently lead CDx development for multiple projects in the oncology portfolio. Prior to Daiichi Sankyo, Flora was at Kyowa Hakko Kirin Pharma as a Senior Manager. At KHK she focused on strategic biomarker selection, development and translation into CDx assays. She was the CDx lead on representing the strategies to external partners and regulatory agencies. Prior to KHK, Flora was at Bristol­Myers Squibb where she progressed through the ranks gaining valuable experience in GLP and clinical Bioanalysis, biomarker and CDx assay development from design control through commercialization. In addition to Flora’s industry experience, she is currently an Adjunct Professor in the Department of Biology at CUNY (City university of New York) where she teaches anatomy­physiology and biology over a decade.

Jennifer Dacpano-Komansky

Director, Regulatory Affairs & Precision Medicine

Novartis

×

Jennifer Dacpano-Komansky

Director, Regulatory Affairs & Precision Medicine

Jennifer Dacpano-Komansky is currently a Director for Novartis Global Regulatory Affairs where she supports Precision Medicine within the Oncology division. In this role, she is responsible for providing regulatory guidance specializing in diagnostic development strategies associated with oncology and immuno-oncology therapeutic  trials.  Prior to joining Novartis, Jennifer came from Leica Biosystems where she established her career in companion diagnostics serving as an IVD Product Development Scientist and later as a Regulatory Affairs Specialist. In addition, her exposure to FDA and regulated GxP-environments include her decade-long employment working in the Preclinical Drug Safety Investigative Pathology division at Sanofi-Aventis. Jennifer’s broad range of experience includes: quality systems, design control development, database validation, CDx partnership/technology regulatory assessments, clinical trial design, liquid biopsy initiatives, premarket applications and post market IVD surveillance reporting.

Julie Engel

Director of Precision Medicine and Diagnostics Regulatory Affairs

Celgene

×

Julie Engel

Director of Precision Medicine and Diagnostics Regulatory Affairs

Julie Engel is the newly appointed Director of Precision Medicine and Diagnostics Regulatory Affairs at Celgene. Prior to joining Celgene, Julie was the Director of Companion Diagnostics Regulatory Affairs at Ventana Medical Systems (Roche Tissue Diagnostics) Tucson, Arizona where she gained PMA approvals for the ALK IHC assay for NSCLC, and the PDL-1 (SP142) IHC assay for bladder carcinoma and NSCLC. Prior to joining Celgene, Julie held positons in both mid-large Pharma (Regeneron, Lilly) as well as emerging Pharma companies (Pharmacyclics, Endocyte, Cytheris, ImClone) in both clinical research and Regulatory affairs. For the past six years, she has focused on Companion Diagnostics, first at Roche Professional Diagnostics in Indianapolis, Indiana, with a focus in CNS diseases, and more recently at Roche Tissue Diagnostics (Ventana Medical Systems, Inc.), with a focus in oncology.

Julie holds a PhD degree in Basic Medical Sciences from the New York University School of Medicine, and a Regulatory Affairs Certification (RAC).

Warren Glaab

Director, Systems Toxicology Investigative Laboratory Sciences

Merck Research Laboratories

×

Warren Glaab

Director, Systems Toxicology Investigative Laboratory Sciences

Dr. Warren Glaab has worked within Safety Assessment at Merck Research Laboratories for 20 years. Most recently he has served as Director of Systems Toxicology, involved with providing biomarker development support to Safety Assessment, incorporating new model systems and technologies including genomics and proteomics, and investigative toxicology research solutions. Previous experience within the Department of Molecular and Investigative Toxicology group in Safety Assessment included novel assay development and investigational studies to better understand toxicity mechanisms. He earned his Ph.D. in Toxicology at the University of North Carolina at Chapel Hill, conducted research at the National Institute of Environmental Health Sciences in Research Triangle Park, and completed two postdoctoral positions at National Institute of Environmental Health Sciences and at Merck Research Laboratories in West Point, PA.

Junchen Gu

Research Investigator

Bristol-Myers Squib

×

Junchen Gu

Research Investigator

Junchen is currently a Research Investigator in Translational Bioinformatics IO/Oncology at Bristol-Myers Squibb in Princeton, NJ. He is part of a large group of bioinformaticians that support projects from discovery through translational research and clinical development at BMS.

Junchen earned his BS degrees in Plant Sciences from Cornell University and China Agricultural University, and then completed a PhD in Molecular Genetics and Genomics at Washington University in St. Louis. His research experiences have involved studies of the epigenomes in human and mouse using both experimental and computational approaches, and investigation of the genetic basis of pediatric brain diseases. Junchen has extensive experiences in next-generation sequencing based assay design and analysis and most recently was developing bioinformatics tools for plasma based early cancer detection at Singlera Genomics Inc in San Diego prior to joining BMS.

Sarah Hersey

Head of Precision Medicine and Companion Diagnostics

Celgene

×

Sarah Hersey

Head of Precision Medicine and Companion Diagnostics

Sarah is currently the Head of Precision Medicine and Companion Diagnostics for Celgene Corporation.  She has more than 20 years’ of industry experience in leading R&D organizations, CLIA laboratories, device manufacturing, assessment and implementation of technology strategies and development of in vitro diagnostics.   Prior to joining Celgene, Sarah was at Novartis, initially as an Executive Director, Global Program Diagnostics and subsequently moved into the role of Global Head of Future Precision Medicine, leading a team which submitted multiple pre-market applications including one for NGS.   Prior to Novartis, Sarah held multiple roles with increasing responsibility within Johnson and Johnson including Global Head of Operations, Assay Program Leader for Companion Diagnostics Center of Excellence, Director of Materials Process Development and Enabling Technologies.  In addition, her prior experience includes start-up and establishment of a pre-clinical GLP laboratory, technical support and quality assurance.  Sarah has BS and MS degrees in Chemistry and Biology from Northern Illinois University, Regulatory Affairs Certification (RAC) and MBA from California State University.

George Lee

Digital Pathology Informatics Lead

Bristol-Myers Squibb

×

George Lee

Digital Pathology Informatics Lead

George Lee received his PhD in Biomedical Engineering at Rutgers University and has over 10 years of expertise in the areas of digital pathology, machine learning, and clinical oncology. He is an author on over 30 peer-reviewed manuscripts and abstracts and holds several patents for image-based CDx. Currently, at BMS, he is facilitating and managing partnerships with image analysis vendors to develop and validate pathology image-based pipelines for the purpose of exploratory hypothesis generation and companion diagnostics. Previous to working at BMS, he worked as a Research Assistant Professor at Case Western Reserve University developing machine learning and image-analysis methodologies for predicting the progression of prostate cancer.

Andrew Levitch

Founder and Managing Director

Finategy

×

Andrew Levitch

Founder and Managing Director

TBA

Kamala Maddali

Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics

Cancer Genetics

×

Kamala Maddali

Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics

Dr. Kamala K Maddali is currently Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc, Rutherford, NJ. Cancer Genetics, Inc. (CGI) is a leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology.

Dr. Maddali holds a DVM Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India.

Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She has promoted the proper utilization of biomarkers, personalized medicine and diagnostics in drug development and patient management to bridge the gap between drug and diagnostic industries. She was Global Director Scientific Development -Biomarkers & Companion Diagnostics for Q2 Solutions (A Quintiles & Quest Diagnostics joint venture). She brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.

Matthew J. Marton

Director, Companion Diagnostics & Genomics

Merck & Co.

×

Matthew J. Marton

Director, Companion Diagnostics & Genomics

Matthew Marton is Director of Clinical Genomics in Merck & Co.’s Molecular Biomarkers & Diagnostics department, where his team has deployed predictive biomarkers as patient enrichment assays on multiple technology platforms in over a dozen Merck clinical studies. His current work focuses on the CoDx strategy of novel genomic assays as molecular diagnostics, and he is a contributor to several CLSI documents involving molecular diagnostic testing in oncology. Prior work at Merck focused on technology/method development and biomarker discovery, with an emphasis on quality control of molecular profiling assays. Earlier in his career, Dr. Marton worked with Drs. Stephen Friend and Lee Hartwell at the Seattle Project, a drug discovery think tank, which led to the founding of Rosetta Inpharmatics, a biotechnology company that was acquired by Merck in 2001. At Rosetta and subsequently at Merck, he led scientific efforts to create a GLP-like high throughput functional genomics laboratory. Dr. Marton completed post-doctoral training at the NIH and holds a PhD from Princeton University and a Certificate in Biomedical Regulatory Affairs from the University of Washington.

John S. Mudgett, Ph.D.

Vice President, Drug Discovery Services

Genesis Biotechnology Group

×

John S. Mudgett, Ph.D.

Vice President, Drug Discovery Services

John S. Mudgett, Ph.D. is Vice President, Genesis Drug Discovery Services at the Genesis Biotechnology Group.  Leading the integration of all drug discovery services groups and functions, John brings an enthusiastic vision and decades of internal and external pharmaceutical experience to create and grow a holistic customer facing Services Company.

Dr. Mudgett, was owner of JsM BioScience, LLC, providing science and business development consultation services to Biotech, CRO, and Scientific Conference business.  His services included opportunity assessment, and science and business evaluation for client penetration into the Pharma and Biotech customer base.  

Prior to that, John was External Lead – Pharmacology, Merck Research Laboratories, a position with increasing responsibilities he held for 12 years.  At Merck, he brought extensive experience in the execution of scientific, business development, managerial, financial, Lean Sigma, and IT delivery for translational BioPharma support of a diverse portfolio of programs in the global CRO arena.

John was a founding member of the GEM department, tasked with taking an entrepreneurial approach to partnering with internal research to create an inception-to-impact return on investment with external providers in the US and global arenas.  John was responsible for domestic and global scientific and business development, CRO alliance management, external project management, internal-external collaborations, and delivery of pipeline supporting data for program advancement.  Awarded the Merck Research Laboratories Customer Focus Award, he was recognized for bringing value and experience to both internal and external customer needs and business solutions.

Dr. Mudgett holds Doctorate and Masters degrees from The Pennsylvania State University and a B.S. with high distinction from The University of Maine.  He has completed postdoctoral training at Los Alamos National Laboratory, where he was awarded the Alexander Hollaender Postdoctoral Fellowship Award.  He is a Six Sigma certified greenbelt, and led an effort that returned $30 million to Merck in efficiencies, while increasing the scientific deliverables.

John serves as a Scientific Advisor to the Panel of Scientific Consultants for the International Mouse Phenotyping Consortium (IMPC), funded by the NIH Common Fund.  He also serves as a member of the Scientific Advisory Board for PHENOMIN, the French National Infrastructure for Mouse Phenogenomics.  In addition, John is a member of the BioPharma Research Council committee for helping to organize speakers and conference sessions for upcoming events.  John and his wife Kristine are actively involved in Preschool Advantage, a charitable organization serving children and families of need in obtaining quality preschool access and tuition.  In addition, John is an avid wood craftsman, making custom wood-crafted products.

Mark Parrish

Director

Covance

×

Mark Parrish

Director

Mark Parrish has over 17 years of experience dedicated to the development of high throughput, high quality genomics tools for drug development. He has cultivated a diverse publication record, having published in the areas of plant sciences, molecular biology, genomics, and medicine. He has a broad knowledge of numerous platforms and technologies for gene expression, genotyping and microRNA profiling. He was a founding scientist of the Rosetta Inpharmatics Gene Expression Laboratory, the industry-leading provider of genomics services, later acquired by Merck and Covance. He led the development, implementation and validation of a number of platforms and assays, including the industry’s highest throughput gene expression systems. Mark built the Biomarker Translation department, a team focused on the development and validation of targeted genomics assays across a variety of platforms (qPCR, nanoString, Exiqon, etc). He was responsible for the day-to-day operations for the Applied Genomics department, which included all functions from nucleic acid extraction, array and targeted genomics assays and data delivery. Currently, Mark is the Director of Project Management, working with clients to leverage the full breadth of Covance and LabCorp genomics capabilities.

Oscar Puig

Chief Scientific Officer

Phosphorus

×

Oscar Puig

Chief Scientific Officer

Oscar Puig is the Chief Scientific Officer at Phosphorus, a genetic diagnostic company founded in 2016 that develops diagnostics for complex genetic diseases and software for clinical data management and analysis. We currently commercialize three genetic panels (Reproductive Health, Cardiology, and Oncology). Prior to that, he was a Biomarker Leader in Oncology at the Roche Innovation Center in New York. He earned his Ph.D. at the University of Valencia, Spain, and carried out postdoctoral research at the European Molecular Biology Laboratory, in Heidelberg, Germany, and in the lab of Bob Tjian, at UC Berkeley, CA. Before joining Roche in 2012, he worked at Merck and at the University of Helsinki, where he is a docent. Dr Puig has over 40 publications in peer-reviewed journals.

Mark Roberts

Director, Diagnostics Development

Covance

×

Mark Roberts

Director, Diagnostics Development

Mark J. Roberts, received his PhD in Pharmaceutical Sciences from the University of Nottingham (UK) and has worked in the clinical diagnostics arena for over 20 years, holding senior positions in both the in vitro diagnostic and reference laboratory industries. He joined Covance in 2012 to spearhead our Companion Diagnostics initiative, designed to assist pharmaceutical and diagnostic companies in drug – companion diagnostic co-development.

Aaron Schetter

Scientific Reviewer, Division of Molecular Genetics and Pathology

U.S. Food and Drug Administration

×

Aaron Schetter

Scientific Reviewer, Division of Molecular Genetics and Pathology

Aaron Schetter, PhD MPH, is scientific reviewer in the Division of Molecular Genetics and Pathology/Office of in vitro Diagnostics/CDRH/FDA where he performs premarket review of molecular- and immunohistochemistry-based in vitro diagnostics for a variety of oncology indications. He earned his PhD in molecular biology and Genetics from Cornell University and MPH focusing on epidemiology and biostatistics from University of California at Berkeley. Prior joining the FDA in 2014, Aaron spent 10 years at the National Cancer Institute where he focused on molecular profiling of various tumor types to identify potential biomarkers and therapeutic targets. His research has led to (co)authorship for over 50 manuscripts in peer-reviewed journals and 9 US patents.

Bob Silverman

Personalized Healthcare (PHC) Business Strategy & Partnering

Roche Diagnostics

×

Bob Silverman

Personalized Healthcare (PHC) Business Strategy & Partnering

Bob’s is in a newly established role at Roche, in the Diagnostics division with dual responsibilities at both a divisional and operational level. From 2013 until his current role Bob Silverman led the “External Drug Discovery Partnering” team of Roche Partnering. Among other matters, Bob was responsible for delivering a structured and systematic approach to venture capital that translates to reach into drug discovery stage innovation via deals originating from venture capital interactions. Prior, from 2010 – 2012 Bob was a project leader for Merger & Acquisitions, in the Strategic Partnering Group of Roche Partnering. From 2003 – 2010 Bob was a Global Licensing Director for Roche Pharma Partnering, responsible for negotiating intellectual property based licensing agreements across the full value chain of the Pharma business, ranging from enabling technologies and early phase opportunities to clinical stage assets to promoting and divesting marketed products. From 2001 – 2003 Bob was a Global Licensing Attorney. Bob joined Roche in 1993. Early in his career at Roche Bob was Senior Counsel for the US Affiliate patent department. Bob holds a degree in Chemistry from Franklin & Marshall College and a J.D. from Boston University School of Law, and is a registered patent attorney.

Donald Very

President and CEO

Naviter Bioanalytics

×

Donald Very

President and CEO

With over twenty-five years of diagnostic assay development and performance qualification experience in such diverse clinical areas as oncology, infectious disease, and metabolic disease, Dr. Very has extensive experience in all phases of diagnostic assay research, development, performance validation, clinical trial design and implementation, and regulatory approval.

Dr. Very is currently President, CEO, and Founder of Naviter Bioanalytics, LLC, a private consulting firm specializing in bioanalytical method development, performance qualification, and regulatory approval.  Previously, Dr. Very served as Vice President, Scientific Strategy, Technology and Research at Helomics Corporation where he was responsible for the identification, evaluation, and implementation of new technologies, assay platforms, and tests to augment the company’s clinical laboratory, comprehensive tumor profiling platform, and contract research offerings.  Prior to Helomics, he was Vice President of Research and Assay Development for Ancera, Inc., where he successfully led efforts to develop quantitative cell, nucleic acid, and protein assays for the company’s proprietary, magnetic fluid-based, diagnostic platform; and Vice President of Immunology and Assay Development for the Institute for Bioanalytics, LLC (IBA), where he was ersponsible for the overall scientific, operational, and research activities of the Institute.  At IBA, he successfully built a profitable contract research business.  Under his leadership, IBA completed over 200 cell, nucleic acid or antibody-based assay development and performance qualification projects in support of the research programs of clients in the pharmaceutical, diagnostic, and biotechnology industries.  Dr. Very also served as a Senior Research Scientist for the Diagnostics Division of Bayer Corporation, where he was responsible for the design and execution of clinical trials, performance validation studies for the AFP, CA 125 II, and CA 15-3 tumor marker assays for the Bayer Immuno 1™ Immunoanalyzer, and the preparation and submission of 510(k) applications to the FDA for these assays.  These activities culminated in the FDA’s approval of all these assays for use in the U.S.  Dr. Very began his career as a researcher and supervisor of the BL-2 and BL-3 laboratories affiliated with the U.S. Army Medical Research Unit in the Republic of Korea.  Managing a staff of six scientists, his team conducted clinical and diagnostic research on hantaviral and rickettsial diseases endogenous to the Korean peninsula.

Dr. Very is a frequently invited speaker at national and international scientific symposia discussing topics ranging from advances in personalized medicine in oncology, the clinical utility of serum biomarkers in the diagnosis and management of disease, the development and performance qualification of multiplexed immunoassays, and the future of the in vitro diagnostic industry.  He received his Bachelor of Science degree in Biology from the University of Notre Dame, a Master of Science degree in Biology from the University of Texas at San Antonio, and a Doctorate in Microbiology/Immunology from Boston University.

Russ Weiner

Executive Director

Daiichi Sankyo

×

Russ Weiner

Executive Director

Russell Weiner is currently Executive Director and Global Head Bioanalytical, Biomarkers and Companion Diagnostics at Daiichi Sankyo. He is an experienced senior level biopharmaceutical professional with direct expertise in drug discovery and development, clinical trial conduct and building regulated bioanalytical (GLP and clinical), molecular biomarker and companion diagnostic organizations. He has over 24 years experience having worked at Bristol-Myers Squibb, Merck and now Daiichi Sankyo in all therapeutic areas with a focus on immuno-modulatory/immuno-oncology (checkpoint blockers) therapeutics. He was directly involved in supporting the development and approval of Erbitux® (cetuximab, ant-EGFR), Orencia® (abatacept, CTLA4Ig), Nulojix® (belatacept, mutated CTLA4Ig), Yervoy® (ipilimumab, anti- CTLA4), Keytruda® (pembrolizumab, anti-PD- 1) and its associated Dako PD-L1 IHC 22C3 pharmDx companion diagnostic assay. Russ has extensive experience in project leadership,
biologics/biomarker assay development, validation and global deployment (including India, China, Singapore and Japan). He has led early clinical development teams responsible for transitioning multiple small molecule immunology/inflammation therapeutics from discovery through phase 2 proof-of- concept. Russ is a strategic thinker well versed in using biomarkers for early decision making, companion diagnostics for patient selection and is a recognized thought leader on regulated bioanalysis and biomarker assay development.

Katarina Wikstrom

Head of US Operations

Almac Diagnostics

×

Katarina Wikstrom

Head of US Operations

Dr. Katarina Wikstrom (PhD) has worked for over 14 years in the field of translational molecular oncology and holds the position of Head of US Operations at Almac Diagnostics. Katarina has overall responsibility for all US laboratory technologies and services supporting biomarker discovery, assay development and validation, and product delivery.

Katarina obtained a PhD in experimental pathology from Lund University, and subsequently completed a postdoctoral fellowship on the molecular mechanisms of prostanoid signaling in vascular haemostasis and oncology at University College Dublin. Since joining Almac in 2009 Katarina has built up a breadth of experience in the biomarker field with particular focus on assay development and validation.

Ronnye Schreiber

CEO

PlanetConnect & Board of Directors, BioPharma Research Council

×

Ronnye Schreiber

CEO

Ronnye co-founded PlanetConnect in 1995 and is the company CEO. She is also Co-founder and member of the Board of Directors of the non-profit, BioPharma Research Council (BRC).  She leads teams creating customized internal and external meetings and trade shows for Pharmaceuticals, Telecommunications and AgBio organizations. Past working lives have been spent in labs in Johnson & Johnson, Rutgers Medical School, Sidney Farber Cancer Institute, Arthur D. Little, and Ortho Diagnostics and in libraries and marketing at AT&T and Lucent Bell Laboratories.

Tom Fare

Director of Strategic Alliances

PlanetConnect

×

Tom Fare

Director of Strategic Alliances

Tom is Director, Strategic Alliances for PlanetConnect. His role is to engage potential new clients and customers to develop symposia that address existing and emerging needs within their organizations.  He uses his extensive experience in scientific research, development, and licensing to identify meeting themes matched to a client’s objectives and goals.  He also develops ROI models to measure and report on business and employee development for clients and customers.   Tom spent over 13 years with Merck & Co. and over 30 years in biotechnology and technology.  He received his PhD in Electrical Engineering and Science at the University of Pennsylvania.  He has authored or co-authored peer-reviewed papers in fields ranging from circuit design to gene profiling technologies.